Thu, June 30, 2011
Wed, June 29, 2011
Tue, June 28, 2011
Mon, June 27, 2011
Sat, June 25, 2011
Fri, June 24, 2011
Thu, June 23, 2011
Wed, June 22, 2011
Tue, June 21, 2011
Mon, June 20, 2011
Sun, June 19, 2011
Fri, June 17, 2011
Thu, June 16, 2011
Wed, June 15, 2011
Tue, June 14, 2011
[ Tue, Jun 14th 2011 ] - Market Wire
Bond Labs Reports May Results
Mon, June 13, 2011
Fri, June 10, 2011
Thu, June 9, 2011
Wed, June 8, 2011
Tue, June 7, 2011
Mon, June 6, 2011
Sat, June 4, 2011
Fri, June 3, 2011
Thu, June 2, 2011

Bio-Path Holdings to Present at the OneMedForum NY Conference


//health-fitness.news-articles.net/content/2011/ .. to-present-at-the-onemedforum-ny-conference.html
Published in Health and Fitness on Friday, June 17th 2011 at 6:41 GMT by Market Wire   Print publication without navigation


HOUSTON--([ BUSINESS WIRE ])--Bio-Path Holdings, Inc. (OTCBB: BPTH) (aBio-Patha), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the OneMedForum NY Conference in New York City on Thursday, June 23, 2011 at 12:00 p.m. Eastern Time.

A webcast ofMr. Nielsena™s remarks will be available live. You can access the webcast at: [ www.onemedplace.com ].

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Patha™s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. Bio-Patha™s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors, and its third candidate is a liposomal siRNA cancer drug that is in the final pre-clinical development stage. These product candidates and the delivery technology have been licensed from The University of Texas MD Anderson Cancer Center.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Patha™s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q.These documents are available on request from Bio-Path Holdings or at [ www.sec.gov ].Bio-Pathdisclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at [ http://www.biopathholdings.com ].


Publication Contributing Sources